A study suggests that an experimental drug may modestly extend the lives of men with advanced prostate cancer who are no longer responding to other treatments.
The drug, cabazitaxel (kuh-BAH-zuh-TAX-uhl), helped men live an average of 10 weeks longer in a large study sponsored by the drug's maker, Sanofi-Aventis. Researchers hope the drug can make more of a difference in men who aren't so sick. The federal Food and Drug Administration has said it will give the drug fast review.
Viewers with disabilities can get assistance accessing this station's FCC Public Inspection File by contacting the station with the information listed below. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, 888-835-5322 (TTY), or firstname.lastname@example.org.